Teva Australia
Pharmaceuticals
Teva established its Australian branch in 2014.

Overall

Owned ISR
Rating D
About the Ratings

Company Ownership

Teva Pharma Australia Pty Ltd
AUS
Teva Pharmaceutical Industries Ltd
owns 100% of Teva Pharma Australia Pty Ltd
ISR
Pharmaceuticals
Established in Jerusalem in 1901, today they are the world's largest producer of generic pharmaceuticals. Acquired Actavis Generics from Allergan in 2016 for US$40.5 billion.

Company Assessment

(Last updated Aug 2024)
Teva Pharma Australia Pty Ltd
No assessment data currently available for Teva Pharma Australia Pty Ltd.
Teva Pharmaceutical Industries Ltd
Praise
CDP Climate Change score of A-
In 2023, the Carbon Disclosure Project (CDP) asked companies to provide data about their efforts to reduce greenhouse gas emissions and mitigate climate change risk. Responding companies are scored across four key areas: disclosure; awareness; management; and leadership. This company received a CDP Climate Change score of A-.
Source: CDP (2023)
CDP Water Security score of B
In 2023, the Carbon Disclosure Project (CDP) asked companies to provide data about their efforts to manage and govern freshwater resources. Responding companies are scored on six key metrics: transparency; governance & strategy; measuring & monitoring; risk assessment; targets & goals; and value chain engagement. This company received a CDP Water Security score of B.
Source: CDP (2023)
68/100 in TIME rankings
World's Most Sustainable Companies of 2024 by TIME and Statista recognises the Top 500 most sustainable companies in the world. From a selection of 5,000 of the world's largest companies, non-sustainable businesses were excluded, and the remaining companies were rated on Commitment & Ratings, Reporting & Transparency, and Environmental & Social Stewardship. This company received a total score of 67.7/100, ranking 143rd overall.
Source: TIME (2024)
Criticism
$4.35b opioid settlement
In 2022 this company agreed to pay US$4.35 billion to put an end to thousands of complaints alleging the company exacerbated the U.S. opioid epidemic.
Supply chain practices in China
The Green Supply Chain Corporate Information Transparency Index (CITI) evaluates consumer-facing companies that have a sizeable supply chain in China. The evaluation uses government supervision data and public information to assess the environmental management of their supply chains in China. This company received a score of 12.14/100 (retrieved 24 Nov 2023).
Source: IPE (2023)
7/20 in Social Benchmark
The 2024 Social Benchmark assesses the world's 2,000 most influential companies on their responsibility in meeting society's fundamental expectations towards three measurement areas: respecting human rights, providing decent work, and acting ethically. This company was assessed in 2022 and received a score of 7/20. The average score was an alarmingly low 4.6/20 and the highest score was 15.5/20.
$135m fraud settlement in USA
In 2019 several pharmaceutical companies finally settled a 2005 lawsuit which claimed the companies fudged wholesale drug prices to increase Medicaid reimbursements. In all, the state of Illinois received a combined $648 million over the course of that litigation. This company paid US$135 million to wrap up the allegations in 2019.
Information
Pollution in China
A 2015 report by Sum Of Us reveals that the largest pharmaceutical corporations are complicit in fuelling one of the most serious public health crises facing society today. Pharmaceutical companies, including this one, are sourcing active pharmaceutical ingredients (APIs) from companies in China which are responsible for massive environmental pollution from its antibiotic factories. Teva has links with at least three of the Chinese companies identified in the report, all of which have been in the Chinese media spotlight for various offences including improper waste management and the release of noxious chemicals.
34.2% in Newsweek Green Ranking 2017
This company received a score of 34.2/100 in the Newsweek Green Ranking 2017, which ranks the world's largest publicly traded companies on eight indicators covering energy, greenhouse gases, water, waste, fines and penalties, linking executive pay to sustainability targets, board-level committee oversight of environmental issues and third-party audits. Ranking methodology by Corporate Knights and HIP Investor.
$519m bribery settlement
In 2016 this company agreed to pay more than $519 million to settle US criminal and civil allegations that the company bribed officials in Mexico, Russia and Ukraine to gain business for its medications. [Listed under Information due to age of court finding]
$1.2b antitrust settlement
In 2015 this company agreed to pay US$1.2 billion to settle charges that one of its subsidiaries illegally blocked the launch of low-cost generic versions of the blockbuster sleeping pill Provigil. The settlement stems from charges brought in 2008 against Cephalon Inc, which was acquired by Teva in 2012.
Product carbon footprint label
This company has products that are certified by the Carbon Trust, signifying that the carbon footprint of selected products has been measured, managed and reduced. A life cycle product carbon footprint is determined by calculating the total greenhouse gas emissions generated by a product, from extraction of raw-materials, to end-of-life.
Climate action commitments
As listed on the We Mean Business website, this company has committed to the following climate action initiatives: adopt a science-based emissions reduction target.
Gender equality
This company appears on the 2023 Bloomberg Gender-Equality Index, signifying a commitment to supporting gender equality through policy development, representation, and transparency.
Responsibility claims
This company has Responsibility claims on its website.
AMR Industry Alliance member
This company is a member of the AMR Industry Alliance, a coalition of biotech, diagnostics, generics and research-based pharmaceutical companies set up to provide sustainable solutions to curb antimicrobial resistance (AMR). AMR is an increasingly significant threat to global public health which puts at risk the effective prevention and treatment of a wide range of infections.
60% in AMR Benchmark
The 2021 Antimicrobial Resistance (AMR) Benchmark ranks 17 large pharmaceutical companies on their efforts keep medicines and vaccines available, despite the rise of drug resistance. This company received a score of 60%.
54/100 S&P Global ESG Score
This company received an S&P Global ESG Score of 54/100 in the Pharmaceuticals category of the S&P Global Corporate Sustainability Assessment, an annual evaluation of companies' sustainability practices (last updated 16 Dec 2022). The rankings are based on an analysis of corporate economic, environmental and social performance, assessing issues such as corporate governance, risk management, environmental reporting, climate strategy, human rights and labour practices.
21.7% in Nature Benchmark
The Nature Benchmark ranks 816 companies across 20 industries on their efforts to protect our environment and its biodiversity. Companies were assessed in three phases between 2022 and 2024 using three measurement areas: governance and strategy; social inclusion and community impact; and ecosystems and biodiversity. This company was assessed in 2022 and is ranked #218/816, with a total score of 21.7/100.
> About the Icons

Company Details

Type:
Wholly-owned subsidiary

Contact Details

Address:
Level 2, 37 Epping Road, Macquarie Park, NSW, 2113, Australia
Phone:
02 8061 9999
Freecall:
1800 288 382
Website:
www.tevapharm.com

Products / Brands

Teva Australia
Infacol Baby Toiletries
Sudocrem Baby Toiletries